Kilitch Drugs (India) Ltd
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
- Market Cap ₹ 521 Cr.
- Current Price ₹ 324
- High / Low ₹ 470 / 298
- Stock P/E 23.6
- Book Value ₹ 147
- Dividend Yield 0.00 %
- ROCE 10.2 %
- ROE 7.98 %
- Face Value ₹ 10.0
Pros
- Company's median sales growth is 15.1% of last 10 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.27% over last 3 years.
- Earnings include an other income of Rs.13.3 Cr.
- Company has high debtors of 171 days.
- Working capital days have increased from 77.8 days to 112 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
33 | 15 | 19 | 21 | 27 | 50 | 96 | 61 | 70 | 105 | 118 | 132 | 148 | |
37 | 19 | 21 | 24 | 27 | 44 | 79 | 59 | 65 | 94 | 100 | 111 | 130 | |
Operating Profit | -4 | -4 | -2 | -3 | -0 | 6 | 17 | 2 | 5 | 11 | 17 | 20 | 18 |
OPM % | -11% | -25% | -9% | -15% | -0% | 12% | 18% | 3% | 8% | 11% | 15% | 16% | 12% |
8 | 6 | 3 | 2 | 1 | 3 | 4 | 6 | 4 | 5 | 5 | 6 | 13 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
Depreciation | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 3 | 1 | -1 | -2 | -0 | 7 | 20 | 5 | 8 | 14 | 19 | 23 | 28 |
Tax % | -0% | -10% | -79% | -18% | -91% | 13% | 24% | 15% | 18% | 24% | 19% | 25% | |
3 | 1 | -0 | -2 | -0 | 6 | 15 | 4 | 6 | 11 | 16 | 18 | 22 | |
EPS in Rs | 2.48 | 0.89 | -0.14 | -1.55 | -0.03 | 4.52 | 9.62 | 2.89 | 3.98 | 6.76 | 10.09 | 10.93 | 13.70 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 5% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 24% |
5 Years: | 6% |
3 Years: | 23% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 5% |
3 Years: | 47% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 21% |
3 Years: | 18% |
1 Year: | -15% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 6% |
3 Years: | 7% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
Reserves | 106 | 107 | 107 | 105 | 106 | 117 | 136 | 136 | 147 | 162 | 180 | 207 | 221 |
0 | 0 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 31 | 32 | |
18 | 9 | 7 | 8 | 10 | 13 | 12 | 10 | 18 | 34 | 35 | 33 | 38 | |
Total Liabilities | 137 | 129 | 127 | 126 | 130 | 145 | 172 | 174 | 196 | 232 | 252 | 287 | 307 |
9 | 9 | 9 | 8 | 8 | 7 | 8 | 8 | 7 | 14 | 15 | 16 | 18 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 22 |
Investments | 109 | 40 | 72 | 92 | 96 | 101 | 100 | 98 | 106 | 117 | 110 | 121 | 124 |
19 | 79 | 46 | 25 | 26 | 37 | 65 | 68 | 82 | 101 | 126 | 145 | 143 | |
Total Assets | 137 | 129 | 127 | 126 | 130 | 145 | 172 | 174 | 196 | 232 | 252 | 287 | 307 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | -31 | -8 | 18 | 1 | -1 | 7 | 7 | 6 | 5 | 6 | -11 | |
37 | 72 | -31 | -20 | -1 | -2 | -22 | -10 | -5 | -16 | 6 | -10 | |
-47 | -0 | -0 | -0 | -0 | 6 | 15 | 1 | 2 | 8 | 3 | 11 | |
Net Cash Flow | -9 | 41 | -39 | -2 | -0 | 2 | 0 | -1 | 3 | -3 | 15 | -10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 136 | 213 | 243 | 285 | 200 | 150 | 88 | 102 | 120 | 144 | 165 | 171 |
Inventory Days | 21 | 162 | 124 | 110 | 84 | 39 | 33 | 57 | 34 | 30 | 13 | 22 |
Days Payable | 183 | 292 | 123 | 152 | 183 | 108 | 38 | 81 | 127 | 168 | 180 | 144 |
Cash Conversion Cycle | -26 | 83 | 244 | 243 | 101 | 82 | 83 | 78 | 27 | 6 | -3 | 49 |
Working Capital Days | -29 | 102 | 196 | 231 | 130 | 104 | 78 | 96 | 62 | 50 | 71 | 112 |
ROCE % | 3% | -2% | -1% | -2% | -0% | 5% | 12% | 3% | 4% | 7% | 9% | 10% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 9 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Submission of copy of Newspaper publication of extract of financial results for the quarter ended 30th September, 2024 to stock exchanges
-
Board Meeting Outcome for Submission Of Outcome Of Board Meeting
12 Nov - Board approved unaudited financial results for Q2 2024.
- Financial Results For The Quarter Ended 30Th September, 2024 12 Nov
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 11 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jun 2024TranscriptPPT
-
Jun 2023TranscriptPPT
Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.